Registered outcomes18

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

1 to 18 of 18

Download this page as JSON

List	Outcome	Time frame
Primary	the change in the P100 latency of the full-field visual evoked potential (VEP) between baseline and week 26 for each affected eye of participants	Baseline to week 26
Secondary	The change in MF-VEP latency, between baseline and week 26, for those eyes with delayed latency at baseline	Baseline to week 26
Secondary	The change in lesional MTR, between baseline and week 26, for the lesions stratified by location	Baseline to week 26
Secondary	The change in lesional MTR between baseline and week 26, for the lesions stratified by tissue-specific cohort baseline lesional MTR values	Baseline to week 26
Secondary	Adverse events and withdrawals attributable to metformin and/or clemastine	Baseline to week 28
Other	The change, between baseline and week 26, in the N75 and N145 latencies of the full-field VEP	Baseline to week 26
Other	The change in full field VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline	Baseline to week 26
Other	The change in MF-VEP amplitude, between baseline and week 26, for those eyes with delayed latency at baseline	Baseline to week 26
Other	The change in the number of letters read (and the corresponding LogMAR score) on the Sloan 100%, 2.5% and 1.25% acuity charts, between baseline and week 28	Baseline to week 28
Other	The change in colour vision between baseline and week 28	Baseline to week 28
Other	The change in visual fields between baseline and week 28	Baseline to week 28
Other	The change in saccadic latency parameters in the step, antisaccade and Wheeless tasks between screening and week 28	Screening to week 28
Other	The change in retinal nerve fibre layer thickness between screening and week 28	Screening to week 28
Other	The change in MTR of lesional subcomponents and lesional voxels, stratified by location, between baseline and week 26	Baseline to week 26
Other	The change in lesional MTR between baseline and week 26, for different lesion types	Baseline to week 26
Other	The change in MRI T2 lesion load between baseline and week 26	Baseline to week 26
Other	The change between baseline and week 26 measured by different MRI biomarkers of remyelination	Baseline to week 26
Other	The change in EDSS between screening and week 26	Screening to week 26

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT05131828/registered

API reference For AI assistants